What the ACR says about biosimilars


Rigorous research,  safeguards against repeated switching and a need for distinctive naming and post-marketing surveillance are among the main concerns highlighted in the American College of Rheumatology’s position statement on biosimilars. “We agree that less expensive biologic therapies are needed and recognize that biosimilars provide an opportunity to reduce treatment costs; however close monitoring of possible ...


Already a member? Login to keep reading


OR
© 2017 the limbic